MeVis Medical Solutions AG
M3V
ISIN DE000A0LBFE4 / Valor 3537049
MeVis Medical Solutions AG
UMushroom community rating:
About company
MeVis Medical Solutions AG was established to develop and market disease-oriented products based on scientific achievements in the field of research. The company, listed on the stock exchange since 2007, operates in the field of computer-assisted, image-based medical diagnostics and therapy. With a staff of over 140 members, MeVis Medical Solutions AG holds a 49% stake in MeVis BreastCare GmbH & Co. KG, a joint venture with Varex Imaging Deutschland AG. The company focuses on developing AI products and services for the next generation in radiology. Founded in 1997, MeVis originated from the Center for Complex Systems and Visualization at Bremen University, with Prof. Dr. Heinz-Otto Peitgen playing a significant role in its development.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (14.08.2024):
Revenue Growth
In the first half of the 2023/2024 financial year, MeVis Medical Solutions AG reported a revenue of €8,774k, showing an increase from the previous year's €8,472k. This growth was driven by a rise in the sale of licenses and stable maintenance revenue.
EBIT Increase
MeVis Medical Solutions AG's earnings before interest and taxes (EBIT) saw a significant increase, rising from €1,893k in the previous year to €2,735k in the first half of 2023/2024. This improvement was primarily due to lower expenses from currency translation.
Mammography Diagnostics Performance
The company's Mammography Diagnostics segment performed well in the first half of 2024, with an increase in license sales driven by renewed demand. The maintenance business in this segment remained stable compared to the previous year.
Lung Cancer Screening Solutions
MeVis Medical Solutions AG experienced varied results in its lung cancer screening solutions. While license sales for stand-alone and cloud-based Veolity solutions were slightly ahead of the previous year, orders for lung CAD algorithms lagged due to process changes by OEM customers.
Outlook for 2023/2024
For the 2023/2024 financial year, MeVis Medical Solutions AG expects a slight increase in sales to between €18.0m and €18.5m. The company anticipates stable EBIT in the range of €4.5m to €5.0m, driven by slight sales growth and increased personnel costs and other operating expenses.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
48 M
Market cap (USD)
33
Daily traded volume (Shares)
25.2 / 25.2
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
